Closed call · historical reference

H2020-JTI-IMI2-2018-16-single-stage · Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises…